| Literature DB >> 25386244 |
Edyta Biskup1, Valentina Manfé1, Maria R Kamstrup1, Robert Gniadecki2.
Abstract
We have investigated cell growth dynamics and cyclins B1 and E expression in cell lines derived from mycosis fungoides (MyLa), Sézary syndrome (SeAx), and CD30(+) lympho-proliferative diseases (Mac1, Mac2a, JK). Mac1 and Mac2a had the highest growth rate (doubling time 18-28 h, >90% cycling cells) whereas SeAx was proliferating slowly (doubling time 55 h, approximately 35% cycling cells). Expression of cyclin B1 correlated positively with doubling time whereas expression of cyclin E was unscheduled and constant across the investigated cell lines. All cell lines exhibited high expression of PCNA. Thus, we concluded that cyclin B1 could be used for rapid screening of cell proliferation in malignant lymphocytes derived from cutaneous T-cell lymphoma.Entities:
Keywords: cutaneous lymhomas; cyclins; proliferation.
Year: 2010 PMID: 25386244 PMCID: PMC4211480 DOI: 10.4081/dr.2010.e8
Source DB: PubMed Journal: Dermatol Reports ISSN: 2036-7392
Figure 1Growth dynamics of cutaneous T-cell lymphoma cell lines. (A) Measurement of cell doubling time. Cells were seeded in the culture flasks at a density 2×105/mL. Mac1, Mac2a and JK cells were grown in RPMI 1640 medium supplemented with 10% FCS; MyLa and SeAx cells were grown in GlutaMAX Dulbecco modified essential medium (DMEM) supplemented with 1 mM L-glutamine and 10% FCS. Media, supplements, and serum were obtained from GIBCO BRL. Cell counting was performed twice daily by flow cytometry (Becton-Coulter) until the stationary phase was reached. The time required to double the cell population was calculated using GraphPad Prism (GraphPad Software, San Diego Ca, USA). (B) BrdU incorporation rate. Cells were pulsed for 20 min with 10 µM BrdU, fixed in ice-cold 70% ethanol for at least 20 hr, washed with PBS, and incubated in 2 N HCl for 30 min prior to the addition of anti-BrdU mouse antibodies (Becton Dickinson). Goat anti-mouse antibodies labeled with Alexa-Fluor 488 (1:1000; Invitrogen) were applied as secondary antibodies. DNA was stained with 7-amino-actinomycin D (7AAD; Beckman Coulter). The percentage of BrdU positive cells was determined by flow cytometry analysis. BrdU incorporation rate (FL1) was plotted versus cellular DNA content (FL3). Quantification of flow cytometry data is provided in (C).
Figure 2Cyclin B1 and cyclin E expression in cutaneous T-cell lymphoma cell lines. Cells (2×106) were washed in PBS and fixed in ice-cold 70% ethanol for at least 20 hr. Subsequently, cells were washed again, permeabilized using 0.25% Triton-X 100 (5 min) and stained using appropriate antibodies. In the case of cyclin B1 and PCNA staining, primary FITC labeled antibodies were used (diluted 1:50; BD Pharmingen™) for 2 hr. In the case of cyclin E, cells were stained with primary mouse anti-human cyclin E antibodies (1:150; BD Pharmingen™) for 1 hr, followed by 1 hr treatment with secondary goat anti-mouse antibodies labeled with Alexa-Fluor 488 (1:1000; Invitrogen). In all cases the appriopriate isotype control (for direct staining) or secondary control (for indirect staining) was used. DNA was stained with 7-amino-actinomycin D (7AAD; Beckman Coulter). Cellular fluorescence was measured using flow cytometer (Beckman Coulter). Total percentage of positive cells and percentage per cell cycle phase were calculated. Flow cytometry diagrams show cyclin B1 (A) and cyclin E (B) staining in Mac1, MyLa, and SeAx cells. Quantification of flow cytom etry data is shown in (C).